Literature DB >> 8943426

A dominant negative mutant of an IFN regulatory factor family protein inhibits both type I and type II IFN-stimulated gene expression and antiproliferative activity of IFNs.

A M Thornton1, V V Ogryzko, A Dent, R Sharf, B Z Levi, Y Kanno, L M Staudt, B H Howard, K Ozato.   

Abstract

Type I (alpha,beta) and type II (gamma) IFNs elicit antiproliferative and antiviral activities through two distinct transcription pathways involving 1) IRF family proteins and ISGF3, and 2) STAT1. We have employed a dominant negative strategy to study the role of IRF family proteins in eliciting the biologic activities of IFN. A truncated IRF protein retaining the DNA-binding domain (DBD) of ICSBP (a member of the IRF family) was stably transfected into U937 monocytic cells. Clones expressing DBD had markedly reduced ISRE-binding activity and were defective in expressing several type I IFN-inducible genes. STAT1 was one such type I IFN-inducible gene whose expression was also inhibited in DBD clones. As a result, the expression of several IFN-gamma-inducible genes was also inhibited in these clones, indicating functional coupling of the type I and type II IFN transcription pathways. Furthermore, DBD clones grew more slowly than control clones and were refractory to antiproliferative effects of both types of IFNs. We found that IFN treatment of U937 cells leads to a G1 arrest and an increase in underphosphorylated retinoblastoma gene product. However, IFN treatment did not change the cell cycle profile, nor retinoblastoma gene product phosphorylation state in DBD clones. These data indicate that expression of DBD disrupts cell cycle regulatory mechanisms. Combined with the previously noted failure of DBD clones to elicit antiviral activity, the present work shows that IRF family proteins play an integral part in growth control activities of IFNs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943426

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Assembly requirements of PU.1-Pip (IRF-4) activator complexes: inhibiting function in vivo using fused dimers.

Authors:  A L Brass; A Q Zhu; H Singh
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

2.  The histone acetylase PCAF is a phorbol-ester-inducible coactivator of the IRF family that confers enhanced interferon responsiveness.

Authors:  A Masumi; I M Wang; B Lefebvre; X J Yang; Y Nakatani; K Ozato
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

3.  IFN regulatory factor 8 sensitizes soft tissue sarcoma cells to death receptor-initiated apoptosis via repression of FLICE-like protein expression.

Authors:  Dafeng Yang; Suizhao Wang; Craig Brooks; Zheng Dong; Patricia V Schoenlein; Vijay Kumar; Xinshou Ouyang; Huabao Xiong; Guy Lahat; Andrea Hayes-Jordan; Alexander Lazar; Raphael Pollock; Dina Lev; Kebin Liu
Journal:  Cancer Res       Date:  2009-01-20       Impact factor: 12.701

4.  Characterization of two candidate genes, NCoA3 and IRF8, potentially involved in the control of HIV-1 latency.

Authors:  Sandie Munier; Delphine Delcroix-Genête; Laëtitia Carthagéna; Audrey Gumez; Uriel Hazan
Journal:  Retrovirology       Date:  2005-11-23       Impact factor: 4.602

5.  Interferon (IFN) consensus sequence-binding protein, a transcription factor of the IFN regulatory factor family, regulates immune responses in vivo through control of interleukin 12 expression.

Authors:  N A Giese; L Gabriele; T M Doherty; D M Klinman; L Tadesse-Heath; C Contursi; S L Epstein; H C Morse
Journal:  J Exp Med       Date:  1997-11-03       Impact factor: 14.307

6.  Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein.

Authors:  L Gabriele; J Phung; J Fukumoto; D Segal; I M Wang; P Giannakakou; N A Giese; K Ozato; H C Morse
Journal:  J Exp Med       Date:  1999-08-02       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.